Melanoma Clinical Trial
SpotCheck: Comparison of Enhanced Telemedicine Versus In-person Evaluation for the Diagnosis of Skin Cancer
Summary
The overall goal of this research is to develop a platform that can increase patient access to expert skin cancer diagnostic services via telemedicine. This is especially important for medically underserved areas where melanoma outcomes are worse than in areas with greater access to in-person evaluations. If successful, the widespread availability of such services would be combined with public education efforts to encourage individuals with changing skin lesions to seek evaluation. With decreased travel times to high quality diagnostic services, such efforts may decrease the diagnosis of more advanced melanomas (with a concomitant increase in the diagnosis of earlier stage tumors), and potentially decrease melanoma mortality.
Full Description
The purpose of this study is to see whether a teledermatologist can correctly diagnose skin cancer with the same accuracy as an in-person dermatologist. Telemedicine allows health care professionals to remotely evaluate, diagnose, and treat patients (i.e. without seeing you in person). A dermatologist who is not seeing the patient in person is called a teledermatologist. Currently, the standard of care, which means the accepted first choice of management, is an in-person evaluation. The telemedicine method that will use in this study is called 'store and forward'. This means the information will be sent to the teledermatologist after the patient leaves the clinic. The teledermatologist will use close-up photos and a device called Nevisense to make the diagnosis.
Eligibility Criteria
Inclusion Criteria:
Be 18 years of age or older
Have 1-3 lesions for evaluation
Exclusion Criteria:
Lesions of the hair-bearing scalp, in the mouth, on the lips, genitalia, nails, on/around the eyes, inside the ear
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
New York New York, 10016, United States
How clear is this clinincal trial information?